A new clinical trial that launched this month is testing a new immunotherapy regimen that could offer hope to people with mesothelioma and other hard to treat cancers. It will be examining an experimental treatment that utilizes CAR-T cells, an immune cell engineered to find and attack cancer cells. The[…]
Pleural Mesothelioma
An International Study on Pediatric Patients With Rare Tumors. (PARTNER)
Primary Outcome Measures Epidemiology Use of International Recommendations Survival of children and adolescents (0-18 years) affected by Very Rare Tumors Inclusion Criteria Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. Written informed consent from the patient and/or[…]
Immunotherapy Benefits and Drawbacks for Treating Mesothelioma
Mesothelioma is a rare and aggressive cancer that creates multiple challenges for patients and caregivers. Immune checkpoint inhibitors have recently shown promise to bring hope to people suffering from this devastating cancer. New data from Australia, however, is questioning their effectiveness and safety. Patients and caregivers must understand immunotherapy and[…]
MARS 2 Trial for Mesothelioma
Pleural mesothelioma is a rare and aggressive cancer that is linked to asbestos exposure. It affects the lining of the lungs. Every year, there are over 2,500 people in the United Kingdom that are diagnosed with the cancer. A study known as MARS 2 investigated if adding surgery to chemotherapy[…]
Multimodal Therapy to Treat Pleural Mesothelioma
Malignant pleural mesothelioma is a deadly cancer that is mainly caused by asbestos exposure. It affects the lungs’ lining. It is a very hard to treat cancer because it is very aggressive and is often diagnosed at a late stage. New surgical and therapeutic methods are offering hope though. A[…]
Prospective Data Collection Initiative on Thoracic Malignancies (DuTOC)
Primary Outcome Measures Progression free survival Secondary outcome Measures Disease free survival Overall survival Health related quality of life Inclusion Criteria Age ≥ 18 years; Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board); Informed consent for longitudinal observational data collection; Exclusion Criteria Mentally[…]
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)
Primary Outcome Measures Overall Survival Secondary Outcome Measures Progression Free Survival Best Response: Objective Response Rate (ORR) Best Response: Disease Control Rate (DCR) Best Response: Clinical Benefit Rate (CBR) Other Outcome Measures Survival Rate at 12 Months Survival Rate at 18 Months Survival Rate at 24 Months Survival Rate at[…]
Analysis of 70 Mesothelioma Cases
Malignant pleural mesothelioma is a severe cancer mainly caused by asbestos exposure. It often appears decades after exposure. Early on, symptoms can be unclear, making it difficult to diagnose. Even though the cancer is rare, a mesothelioma diagnosis is still concerning since there is a lack of treatment options. An[…]
First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis. (FLAT)
Primary Outcome Measures Time to Diagnosis Hospitalization time Secondary Outcome Measures Patient’s discomfort/pain Complications Rate of Non Specific Pleuritis Inclusion Criteria Undiagnosed pleural effusion with the character of a lymphocytic exudate Exclusion Criteria Empyema Transudate pleural effusion. Central airway obstruction by tumor. Existence of extensive adhesions that do not allow[…]
Ageing and Mesothelioma
Mesothelioma, a rare and aggressive cancer mainly caused by asbestos exposure, mostly affects the lining of the lungs, but can also affect the lining of the abdomen, heart, and testicles. Older adults are mostly at risk, especially those who worked with asbestos. A new article from the Australasian Journal on[…]
Skip to content